Insulet Company Insiders
PODD Stock | USD 164.42 1.83 1.10% |
About 80 percent of Insulet's insiders are selling. The analysis of insiders' sentiment of trading Insulet stock suggests that quite a large number of insiders are terrified at this time. Insulet employs about 3 K people. The company is managed by 37 executives with a total tenure of roughly 240 years, averaging almost 6.0 years of service per executive, having 81.08 employees per reported executive.
Patrick Sullivan CEO CEO and President and Director |
James Hollingshead CEO CEO President |
Insulet's Insider Buying Vs Selling
20
Selling | Buying |
Latest Trades
2024-02-28 | Shacey Petrovic | Disposed 11609 @ 162.92 | View | ||
2023-12-22 | Markwayne Mullin | Disposed @ 216.18 | |||
2023-11-13 | Shacey Petrovic | Disposed 20000 @ 164.33 | View | ||
2023-09-19 | Prem Singh | Acquired 1 @ 168.92 | View | ||
2023-08-28 | James Hollingshead | Acquired 5550 @ 181.41 | View | ||
2023-07-12 | Daniel S. Goldman | Disposed @ 285.49 | |||
2023-07-03 | Wayde D Mcmillan | Disposed 1388 @ 282.94 | View | ||
2023-06-20 | Dan Manea | Disposed 175 @ 290 | View | ||
2023-06-05 | Luciana Borio | Disposed 500 @ 283.38 | View | ||
2023-06-01 | Shacey Petrovic | Disposed 15000 @ 271.56 | View |
Monitoring Insulet's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Acquired vs Disposed
Filed vs Not Filed
Insider sentiment refers to the collective sentiment or feeling of Insulet's insiders - typically its officers, directors, and beneficial owners holding more than a certain percentage of the company's stock - about the future prospects of Insulet. This sentiment is often gauged based on the trading activities of these insiders. If insiders are purchasing more shares of their own company, it may be interpreted as a bullish sentiment, indicating that they believe Insulet's stock will rise in value. Conversely, if insiders are selling shares, it might be seen as bearish, suggesting they expect the stock price to drop.
Insulet |
Insulet's Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Insulet's future performance. Based on our forecasts, it is anticipated that Insulet will maintain a workforce of about 3000 employees by May 2024.Insulet's latest congressional trading
Congressional trading in companies like Insulet, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in Insulet by those in governmental positions are based on the same information available to the general public.
2024-04-04 | Senator Tina Smith | Acquired $50K to $100K | Verify | ||
2023-12-22 | Senator Markwayne Mullin | Acquired Under $15K | Verify | ||
2023-07-12 | Representative Daniel Goldman | Disposed Under $15K | Verify | ||
2021-02-16 | Representative Peter Meijer | Disposed $15K to $50K | Verify |
Insulet Management Team Effectiveness
The company has return on total asset (ROA) of 0.0609 % which means that it generated a profit of $0.0609 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.3413 %, meaning that it created $0.3413 on every $100 dollars invested by stockholders. Insulet's management efficiency ratios could be used to measure how well Insulet manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to 0.09. The current year's Return On Capital Employed is expected to grow to 0.11. At present, Insulet's Total Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 1.1 B, whereas Intangibles To Total Assets are forecasted to decline to 0.06.The current year's Net Income Applicable To Common Shares is expected to grow to about 5.6 M, whereas Common Stock Shares Outstanding is forecasted to decline to about 44.7 M.
Insulet Workforce Comparison
Insulet is regarded second in number of employees category among related companies. The total workforce of Health Care industry is at this time estimated at about 9,890. Insulet totals roughly 3,000 in number of employees claiming about 30% of equities under Health Care industry.
The company has Profit Margin (PM) of 0.12 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.26 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.26. Insulet Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Insulet insiders, such as employees or executives, is commonly permitted as long as it does not rely on Insulet's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Insulet insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
---|---|---|---|---|---|
2024-03-01 | 1.0435 | 24 | 23 | 124,841 | 28,401 |
2023-12-01 | 0.2857 | 2 | 7 | 20,000 | 66,202 |
2023-09-01 | 0.4444 | 4 | 9 | 15,010 | 20,346 |
2023-06-01 | 1.5 | 9 | 6 | 10,044 | 21,160 |
2023-03-01 | 0.5424 | 32 | 59 | 159,898 | 157,561 |
2022-12-01 | 0.4615 | 6 | 13 | 48,778 | 95,456 |
2022-09-01 | 0.4 | 2 | 5 | 15,000 | 40,830 |
2022-06-01 | 1.2857 | 9 | 7 | 43,561 | 25,316 |
2022-03-01 | 0.9167 | 33 | 36 | 200,108 | 117,308 |
2021-12-01 | 0.4375 | 7 | 16 | 29,333 | 57,661 |
2021-09-01 | 0.3333 | 3 | 9 | 36,596 | 100,232 |
2021-06-01 | 0.9231 | 12 | 13 | 53,191 | 82,127 |
2021-03-01 | 0.8571 | 24 | 28 | 126,984 | 66,373 |
2020-12-01 | 0.6154 | 8 | 13 | 48,710 | 92,937 |
2020-09-01 | 0.25 | 2 | 8 | 8,392 | 129,944 |
2020-06-01 | 1.4286 | 10 | 7 | 12,921 | 9,098 |
2020-03-01 | 0.9565 | 22 | 23 | 141,163 | 85,580 |
2019-12-01 | 0.5 | 6 | 12 | 23,606 | 40,390 |
2019-09-01 | 0.3333 | 1 | 3 | 2,033 | 4,802 |
2019-06-01 | 1.1053 | 21 | 19 | 78,797 | 97,840 |
2019-03-01 | 0.5294 | 27 | 51 | 190,536 | 207,396 |
2018-12-01 | 0.375 | 3 | 8 | 12,947 | 23,825 |
2018-06-01 | 0.6364 | 14 | 22 | 42,738 | 85,028 |
2018-03-01 | 0.64 | 32 | 50 | 443,529 | 147,848 |
2017-12-01 | 1.0 | 1 | 1 | 2,500 | 1,967 |
2017-09-01 | 2.0 | 6 | 3 | 67,123 | 2,434 |
2017-06-01 | 6.3333 | 19 | 3 | 77,707 | 2,595 |
2017-03-01 | 1.3 | 26 | 20 | 335,781 | 174,818 |
2016-12-01 | 4.0 | 4 | 1 | 52,775 | 3,075 |
2016-06-01 | 2.5714 | 18 | 7 | 112,946 | 17,907 |
2016-03-01 | 2.3636 | 26 | 11 | 639,000 | 81,801 |
2015-09-01 | 1.0 | 3 | 3 | 14,081 | 29,581 |
2015-06-01 | 2.0909 | 23 | 11 | 211,450 | 40,675 |
2015-03-01 | 1.1875 | 19 | 16 | 1,005,711 | 52,117 |
2014-12-01 | 0.625 | 10 | 16 | 1,075,848 | 71,500 |
2014-09-01 | 0.4211 | 8 | 19 | 73,751 | 173,500 |
2014-06-01 | 1.0556 | 19 | 18 | 139,750 | 216,108 |
2014-03-01 | 0.8649 | 32 | 37 | 530,217 | 494,410 |
2013-12-01 | 0.4375 | 14 | 32 | 196,811 | 440,978 |
2013-09-01 | 0.4 | 4 | 10 | 90,000 | 194,000 |
2013-06-01 | 1.1429 | 24 | 21 | 179,647 | 270,323 |
2013-03-01 | 1.5 | 12 | 8 | 274,200 | 125,877 |
2012-12-01 | 0.4615 | 6 | 13 | 100,836 | 165,155 |
2012-09-01 | 0.5909 | 13 | 22 | 153,000 | 206,000 |
2012-06-01 | 1.5417 | 37 | 24 | 661,298 | 316,416 |
2012-03-01 | 0.325 | 13 | 40 | 111,339 | 869,947 |
2011-12-01 | 0.5 | 8 | 16 | 69,500 | 103,299 |
2011-09-01 | 0.6154 | 8 | 13 | 63,200 | 121,900 |
2011-06-01 | 1.1 | 22 | 20 | 176,196 | 270,392 |
2011-03-01 | 0.8788 | 29 | 33 | 752,789 | 409,403 |
2010-12-01 | 0.5 | 1 | 2 | 1,500 | 3,000 |
2010-09-01 | 0.5 | 5 | 10 | 12,000 | 24,000 |
2010-06-01 | 1.0 | 14 | 14 | 37,500 | 27,000 |
2010-03-01 | 0.7273 | 16 | 22 | 158,917 | 185,417 |
2009-12-01 | 0.3846 | 5 | 13 | 10,500 | 38,080 |
2009-09-01 | 1.3333 | 4 | 3 | 37,480 | 12,246 |
2009-06-01 | 1.0 | 3 | 3 | 1,130 | 1,130 |
2009-03-01 | 3.25 | 13 | 4 | 505,000 | 25,000 |
2008-12-01 | 3.0 | 18 | 6 | 43,151 | 15,733 |
2008-09-01 | 0.5714 | 4 | 7 | 44,500 | 9,000 |
2008-06-01 | 1.0 | 7 | 7 | 25,450 | 9,000 |
2008-03-01 | 0.2376 | 24 | 101 | 516,823 | 402,307 |
2007-12-01 | 0.6667 | 2 | 3 | 38,500 | 514,052 |
2007-09-01 | 1.0 | 1 | 1 | 130,000 | 0.00 |
2007-06-01 | 0.5672 | 38 | 67 | 27,125,367 | 47,226,066 |
Insulet Notable Stakeholders
An Insulet stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Insulet often face trade-offs trying to please all of them. Insulet's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Insulet's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Patrick Sullivan | CEO and President and Director | Profile | |
James Hollingshead | CEO President | Profile | |
Eric Benjamin | Senior Vice President R&D, New Product Development and Commercialization | Profile | |
Deborah Gordon | Vice President Investor Relations and Corporate Communications | Profile | |
John Kapples | Senior Vice President General Counsel, Secretary | Profile | |
Wayde McMillan | CFO, Executive Vice President | Profile | |
Charles Alpuche | Senior Vice President Global Manufacturing and Operations | Profile | |
David Colleran | Vice President General Counsel | Profile | |
Brittany Bradrick | Vice President - Strategy and Corporate Development | Profile | |
Aiman AbdelMalek | Senior Vice President Advanced Technology and Engineering | Profile | |
Mark Licari | Vice President - Global Manufacturing and Operations | Profile | |
Michael Spears | Senior Vice President Quality, Regulatory, and Clinical Affairs | Profile | |
Trang Ly | Vice President and Medical Director | Profile | |
Michael Levitz | CFO | Profile | |
Mark Field | Senior CTO | Profile | |
Bradley Thomas | Executive VP of HR and Organizational Devel. | Profile | |
Sally Crawford | Lead Independent Director | Profile | |
John Fallon | Independent Director | Profile | |
Daniel Levangie | Independent Director | Profile | |
James Mullen | Independent Director | Profile | |
Charles Liamos | Director of Advanced Technology and Director | Profile | |
David Lemoine | Independent Director | Profile | |
Jessica Hopfield | Director | Profile | |
Timothy Scannell | Director | Profile | |
Michael Minogue | Independent Director | Profile | |
Steven Sobieski | Independent Director | Profile | |
Corinne Nevinny | Independent Director | Profile | |
Regina Sommer | Independent Director | Profile | |
Joseph Zakrzewski | Independent Director | Profile | |
Philip Hildale | Senior Care | Profile | |
Laetitia Cousin | Quality Affairs | Profile | |
Bret Christensen | Chief Commercial Officer | Profile | |
Deborah CPA | Vice Relations | Profile | |
Prem Singh | Senior Operations | Profile | |
Angela Wiczek | Senior Communications | Profile | |
Lauren Budden | Chief VP | Profile | |
Shacey Petrovic | Chief Commercial Officer | Profile |
About Insulet Management Performance
The success or failure of an entity such as Insulet often depends on how effective the management is. Insulet management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Insulet management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Insulet management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | 0.08 | 0.09 | |
Return On Capital Employed | 0.10 | 0.11 | |
Return On Assets | 0.08 | 0.08 | |
Return On Equity | 0.28 | 0.30 |
The data published in Insulet's official financial statements usually reflect Insulet's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Insulet. For example, before you start analyzing numbers published by Insulet accountants, it's critical to develop an understanding of what Insulet's liquidity, profitability, and earnings quality are in the context of the Health Care Equipment & Supplies space in which it operates.
Please note, the presentation of Insulet's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Insulet's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Insulet's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Insulet. Please utilize our Beneish M Score to check the likelihood of Insulet's management manipulating its earnings.
Insulet Workforce Analysis
Traditionally, organizations such as Insulet use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Insulet within its industry.Insulet Manpower Efficiency
Return on Insulet Manpower
Revenue Per Employee | 565.7K | |
Revenue Per Executive | 45.9M | |
Net Income Per Employee | 68.8K | |
Net Income Per Executive | 5.6M | |
Working Capital Per Employee | 377.2K | |
Working Capital Per Executive | 30.6M |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Insulet. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment. For information on how to trade Insulet Stock refer to our How to Trade Insulet Stock guide.Note that the Insulet information on this page should be used as a complementary analysis to other Insulet's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Complementary Tools for Insulet Stock analysis
When running Insulet's price analysis, check to measure Insulet's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Insulet is operating at the current time. Most of Insulet's value examination focuses on studying past and present price action to predict the probability of Insulet's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Insulet's price. Additionally, you may evaluate how the addition of Insulet to your portfolios can decrease your overall portfolio volatility.
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities |
Is Insulet's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Insulet. If investors know Insulet will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Insulet listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 5.043 | Earnings Share 2.94 | Revenue Per Share 24.331 | Quarterly Revenue Growth 0.379 | Return On Assets 0.0609 |
The market value of Insulet is measured differently than its book value, which is the value of Insulet that is recorded on the company's balance sheet. Investors also form their own opinion of Insulet's value that differs from its market value or its book value, called intrinsic value, which is Insulet's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Insulet's market value can be influenced by many factors that don't directly affect Insulet's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Insulet's value and its price as these two are different measures arrived at by different means. Investors typically determine if Insulet is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Insulet's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.